This release by Public Health Scotland presents information on the number of take-home naloxone kits issued by the National Naloxone Programme in Scotlan
Bibliography: Interventions – Harm Reduction
Physicians’ progress toward ending the nation’s drug overdose and death epidemic
The nation’s continuing increase in drug overdoses is fuelling the evolution of a more dangerous and complicated epidemic (AMA)
Scottish Drug Deaths Taskforce: One Year Report
This report details the work and achievements of the Drug Deaths Taskforce following its establishment in July 2019
Injecting equipment provision in Scotland
This release by Public Health Scotland presents information on the provision of injecting equipmen
Medicinal Use of Psilocybin: Reducing restrictions on research and treatment
The Adam Smith Institute, in conjunction with the Conservative Drug Policy Reform Group (CDPRG), has published a new report outlining the medical potential of psilocybin and the need to reduce restrictions on research and treatmen
A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report
This report describes the development of a national model of remote care to eliminate waiting lists and increase access to OAT in Ireland (BMC)
Summing it up: Building evidence to inform advocacy for harm reduction funding in Asia
Harm Reduction International developed tools for assessing national harm reduction investment and spending on drug law enforcement. This report presents the research findings generated by these tools in seven Asian countries. It provides insights on the state of harm reduction financing, informed by donor and government stakeholders, civil society and community representatives (HRI)
Saving Lives in the time of COVID-19
Case Study of Harm Reduction, Homelessness and Drug Use in Dublin, Ireland (LSE)
Key findings from the ‘Australians’ Drug Use: Adapting to Pandemic Threats’ (ADAPT) Study
The Australians’ Drug Use: Adapting to Pandemic Threats (ADAPT) Study is exploring the short and long-term impact of the COVID-19 pandemic on the experiences of Australians who use illicit drugs (NDARC)
Drugs, Prisons and ‘Unintended Consequences’ – Does drug interdiction drive drug-related harms?
The availability and use of drugs in prisons cannot be separated from wider drug policy. The criminalisation of drugs and the people who use or sell them fuels mass incarceration in many countries, and in doing so creates large profitable markets for drugs behind bars (Gdpo)
Impacts of COVID-19 and associated restrictions on people who use illicit stimulants in Australia
Preliminary findings from the Ecstasy and Related Drugs Reporting System 2020 (NDARC)
Original quantitative research – Setting the baseline
A description of cannabis poisonings at a Canadian pediatric hospital prior to the legalization of recreational cannabis (Public Health Agency of Canada)
Trends in awareness, uptake and deployment of naloxone among a sample of people who inject drugs in Australia
This bulletin describes the awareness of naloxone and the take-home naloxone program in Australia, both nationally and by jurisdiction. It also explores access, use and acceptance of naloxone, and examines demographic differences for these aspects (NDARC)
Adulterants, Contaminants and Co-occurring Substances in Drugs on the Illegal Market in Canada
Provides a snapshot of the contents of drugs on the illegal market in Canada using 2018–2019 data from drug seizures, drug checking services and a drug monitoring study. This bulletin is accompanied by a technical report featuring detailed research methods and data PDF (CCENDU )
COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol
This guidance outlines COVID-19 advice for commissioners and service providers involved in assisting people who are dependent on drugs or alcohol or both (PHE)
Assessing the Evidence on Supervised Drug Consumption Sites
This working paper assesses evidence on and arguments made about supervised consumption sites (RAND)
Clinical guidelines for use of depot buprenorphine (Buvidal® ) in the treatment of opioid dependence (PDF)
This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long-acting injected buprenorphine preparations (SMMGP)
Novel benzodiazepines: prevalence and harms in the UK
This report examines the evidence of prevalence and harms in the UK of several novel benzodiazepines and provides advice to the government (ACMD)
Out of harm’s way (PDF)
This document has been written in response to one of eight recommendations in the West Midlands PCC’s Drugs Policy Report (2018), a report that adopts a new approach that is dictated by evidence and compassion and where the emphasis centres on harm reduction to help to lower crime, save money and support communities (West Midlands Police and Crime Commissioner)
Delivering health and care for people who sleep rough (PDF)
This research starts to answer the question of what needs to be in place for the delivery of joined-up services to a population of people sleeping rough – as a system, rather than a discrete collection of services (King’s Fund)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 18
- Next Page »
